Sana Biotechnology (Sana Biotechnology) Debt-to-Equity : 0.28 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Sana Biotechnology Debt-to-Equity?

Sana Biotechnology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $13.17 Mil. Sana Biotechnology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $92.92 Mil. Sana Biotechnology's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $375.14 Mil. Sana Biotechnology's debt to equity for the quarter that ended in Mar. 2024 was 0.28.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Sana Biotechnology's Debt-to-Equity or its related term are showing as below:

SANA' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.34 Med: 0.17 Max: 0.36
Current: 0.28

During the past 6 years, the highest Debt-to-Equity Ratio of Sana Biotechnology was 0.36. The lowest was -0.34. And the median was 0.17.

SANA's Debt-to-Equity is ranked worse than
63.24% of 1069 companies
in the Biotechnology industry
Industry Median: 0.15 vs SANA: 0.28

Sana Biotechnology Debt-to-Equity Historical Data

The historical data trend for Sana Biotechnology's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sana Biotechnology Debt-to-Equity Chart

Sana Biotechnology Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.34

-0.17

0.15

0.22

0.36

Sana Biotechnology Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.27	0.32	0.27	0.36	0.28

Competitive Comparison of Sana Biotechnology's Debt-to-Equity

For the Biotechnology subindustry, Sana Biotechnology's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sana Biotechnology's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sana Biotechnology's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Sana Biotechnology's Debt-to-Equity falls into.

Sana Biotechnology Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Sana Biotechnology's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(13.195	+	90.901)	/	287.506
	=	0.36

Sana Biotechnology's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(13.167	+	92.922)	/	375.142
	=	0.28

Sana Biotechnology (NAS:SANA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Sana Biotechnology Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Sana Biotechnology's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sana Biotechnology (Sana Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sana Biotechnology Inc (NAS:SANA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

188 East Blaine Street, Suite 400, Seattle, WA, USA, 98102

Website

https://www.sana.com

Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. Its operations include identifying and developing potential product candidates, executing preclinical studies, establishing manufacturing capabilities, acquiring technology, organizing and staffing the Company, business planning, establishing the company's intellectual property portfolio, raising capital, and providing general and administrative support for these operations.

Executives

Christian Hordo	officer: SVP, Chief Business Officer	C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 400, SEATTLE WA 98102
Flagship Ventures Fund V, L.p.	10 percent owner	ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Douglas E Williams	officer: EVP & President, R&D	C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Bernard J Cassidy	officer: EVP & General Counsel	C/O TUMBLEWEED COMMUNICATIONS CORP, 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Patrick Y Yang	director	C/O GENENTECH INC, 1 DNA WAY,MS 49,ATTN:K.STRAND OR J.BERRY, SOUTH SAN FRANCISCO CA 94080-4990
James J. Macdonald	officer: See Remarks	C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 400, SEATTLE WA 98102
Sunil Agarwal	officer: See Remarks	60 LEVERONI COURT, NOVATO CA 94949
Arch Venture Partners Ix, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Flagship Venturelabs V Manager Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund V General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship V Venturelabs Rx Fund, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Venturelabs V Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Arch Venture Fund Ix, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Ix Overage, L.p.	10 percent owner	8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631
Arch Venture Partners Ix Overage, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631